It has been shown that dual mTORC1/2 inhibition mediated by agents such as CC-223 and pp432 is associated with much more effective anti-cancer activity than that associated with mTORC1 inhibition alone [25], due to the negatively regulation of AKT phosphorylation at Ser473, which is the direct downstream target of mTORC2 [23]. The gene discussed is REEP4; the disease is cancer.